| Literature DB >> 29606356 |
Yanmei Han1, Qiuyan Liu1, Jin Hou1, Yan Gu1, Yi Zhang1, Zhubo Chen2, Jia Fan3, Weiping Zhou4, Shuangjian Qiu3, Yonghong Zhang5, Tao Dong5, Ning Li5, Zhengping Jiang1, Ha Zhu1, Qian Zhang1, Yuanwu Ma6, Lianfeng Zhang6, Qingqing Wang7, Yizhi Yu1, Nan Li1, Xuetao Cao8.
Abstract
Identifying tumor-induced leukocyte subsets and their derived circulating factors has been instrumental in understanding cancer as a systemic disease. Nevertheless, how primary tumor-induced non-leukocyte populations in distal organs contribute to systemic spread remains poorly defined. Here, we report one population of tumor-inducible, erythroblast-like cells (Ter-cells) deriving from megakaryocyte-erythroid progenitor cells with a unique Ter-119+CD45-CD71+ phenotype. Ter-cells are enriched in the enlarged spleen of hosts bearing advanced tumors and facilitate tumor progression by secreting neurotrophic factor artemin into the blood. Transforming growth factor β (TGF-β) and Smad3 activation are important in Ter-cell generation. In vivo blockade of Ter-cell-derived artemin inhibits hepatocellular carcinoma (HCC) growth, and artemin deficiency abolishes Ter-cells' tumor-promoting ability. We confirm the presence of splenic artemin-positive Ter-cells in human HCC patients and show that significantly elevated serum artemin correlates with poor prognosis. We propose that Ter-cells and the secreted artemin play important roles in cancer progression with prognostic and therapeutic implications.Entities:
Keywords: Ter-119; Ter-cell; artemin; cancer immunotherapy; erythroblast-like; hepatocellular carcinoma; prognosis biomarker
Mesh:
Substances:
Year: 2018 PMID: 29606356 DOI: 10.1016/j.cell.2018.02.061
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 41.582